Droia is a specialist investor, exclusively focused on the development of oncology and genetic disease therapies.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Droia is a specialist biotech investor with an exclusive focus on therapeutics for oncology and genetic disease. Droia invests globally in newly founded or early-stage platform companies that apply novel science and innovative technologies to bring first-in-class drug candidates to patients. With our team of seasoned scientists, entrepreneurs and investment professionals we build great companies to save patient lives.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2017 | Arcus Biosciences | Series C | 107M |
4/2020 | Accent Therapeutics | Series B | 0 |
5/2020 | QurAlis | Series A | 0 |
1/2017 | OCTIMET Oncology | Series A | 12M |
4/2009 | NormOxys | Venture Round | 4.5M |
9/2016 | Arcus Biosciences | Series B | 70M |
4/2021 | Volastra Therapeutics | Seed | 32M |
3/2018 | Cyteir Therapeutics | Series B | 29M |
1/2017 | Cristal Therapeutics | Venture Round | 0 |
1/2022 | AmbAgon Therapeutics | Series A | 0 |
6/2019 | Frontier Medicines | Series A | 67M |
2/2020 | Montis Biosciences | Seed Round | 0 |
7/2021 | Muna Therapeutics | Series A | 0 |
1/2020 | PACT Pharma | Series C | 0 |
3/2023 | QurAlis | Series B | 0 |
7/2020 | Vico Therapeutics | Series A | 31M |
7/2022 | Vicinitas Therapeutics | Series A | 65M |
2/2021 | Cyteir Therapeutics | Series C | 0 |
5/2021 | Hummingbird Bioscience | Series C | 0 |
3/2023 | Volastra Therapeutics | Series A | 0 |
2/2020 | Volastra Therapeutics | Seed | 12M |
2/2018 | Convert Pharmaceuticals | Series A | 0 |
10/2019 | Cyteir Therapeutics | Series B | 40.2M |
7/2021 | Frontier Medicines | Series B | 0 |
7/2022 | Vicinitas Therapeutics | Series A | 0 |
1/2022 | AmbAgon Therapeutics | Series A | 0 |
7/2021 | Frontier Medicines | Series B | 0 |
7/2021 | Muna Therapeutics | Series A | 0 |
5/2021 | Hummingbird Bioscience | Series C | 0 |
4/2021 | Volastra Therapeutics | Seed Round | 0 |
2/2021 | Cyteir Therapeutics | Series C | 0 |
7/2020 | Vico Therapeutics | Series A | 0 |
5/2020 | QurAlis | Series A | 0 |
4/2020 | Accent Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|